16 May 2025 : Clinical Research
Impact of Sitagliptin on Neprilysin and Glycemic Control in Newly Diagnosed Type 2 Diabetes Patients
Cuma Bulent Gül ABCDEF 1*, Aysegul Oruc CDF 1, Soner Cander ABF 1, Ensar Aydemir
BF 2, Ozen Oz Gül ABCDEFG 1
DOI: 10.12659/MSM.949107
Med Sci Monit 2025; 31:e949107
Table 2 Biochemical parameters at the beginning and the 3rd month of the treatment.
| Parameter | BaselineMean±SD (n=35) | 3rd MonthMean±SD (n=35) | p-value |
|---|---|---|---|
| Fasting blood glucose (mg/dL) | 136.06±34.89 | 129.51±40.54 | 0.086 |
| Postprandial blood glucose (mg/dL) | 213.80±75.44 | 169.37±63.01 | |
| HbA1c (%) | 7.20±1.53 | 6.52±1.89 | |
| AST (U/L) | 21.23±8.52 | 18.91±5.40 | |
| ALT (U/L) | 23.83±10.15 | 21.11±6.81 | |
| Creatinine (mg/dL) | 0.88±0.18 | 0.86±0.19 | 0.275 |
| ACR (μg/mg) | 12.79±18.46 | 13.47±16.30 | 0.544 |
| HOMA-IR | 5.31±3.76 | 5.04±4.21 | 0.561 |
| Total cholesterol (mg/dL) | 203.71±34.83 | 195.91±40.95 | 0.159 |
| HDL-C (mg/dL) | 44.00±9.77 | 43.51±9.30 | 0.61 |
| LDL-C (mg/dL) | 126.71±32.93 | 128.80±37.41 | 0.731 |
| Triglycerides (mg/dL) | 163.89±62.63 | 156.57±77.59 | 0.334 |
| Neprilysin (pg/mL) | 1420.53±1658.64 | 1260.82±1456.57 | 0.789 |
| SD – standard deviation; HbA1c – glycosylated hemoglobin; AST – aspartate transaminase; ALT – alanine transaminase; ACR – albumin creatinine ratio; HOMA-IR – homeostasis model assessment; HDL-C – high-density lipoprotein cholesterol; LDL-C – low-density lipoprotein cholesterol. | |||